![Peer-Spectives artwork](https://is2-ssl.mzstatic.com/image/thumb/Podcasts125/v4/36/e6/62/36e6623f-f57c-fbd4-84fb-34267275b766/mza_11777352931460000686.jpg/100x100bb.jpg)
mRNA Cancer Vaccines: When to Expect FDA Approval, and What’s Next?
Peer-Spectives
English - May 17, 2023 16:56 - 11 minutes - 16.4 MBScience Education obr oncology cancer healthcare medical obroncology peerspectives robertfiglin Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
Recent results demonstrated that mRNA vaccination improved recurrence-free survival among patients with melanoma. This has led to questions about what’s next for this promising intervention. Bob Figlin, MD, the Steven Spielberg Family Chair in hematology-oncology at Cedars Sinai Cancer in Los Angeles, welcomes Jeffrey Weber, MD, PhD, deputy director, professor, and co-director of the melanoma research program at NYU Langone’s Perlmutter Cancer Center, todiscuss potential timing for FDA approval and additional cancers that may see benefit from a vaccine strategy.